Pallas Health GLP1 Reviews (2026): Is It Legit, and What Does It Really Cost?

Affiliate disclosure: Pallas Health is an affiliate partner. The RX Index may earn a commission if you start care through links to Pallas Health, Ro, or another partner. It never changes your price. This page still includes the reasons to choose Pallas and the reasons to skip it.

Last verified: August 21, 2026 · Prices, policies, pharmacies, state rules, and manufacturer programs change. We recheck this page monthly.

The Pallas Health GLP1 reviews we could reproduce were Pallas's own testimonials, two App Store ratings, and editorial or affiliate pages. That is not the same as a mature customer-review record. Here is ours. Pallas Health passes our document-based legitimacy check: it names the company behind it, its clinical network, two physicians, and six pharmacies. But two things should stop you before you enter a card number: the second compounded semaglutide charge is $597, not $139. And Pallas's cash price for brand-name Wegovy is $1,349 a month, while NovoCare Pharmacy lists the same FDA-approved Wegovy pen at $199 for two eligible starter fills and then $349 a month for standard pen doses.

Pallas may fit you if:

• You're paying cash and want compounded semaglutide or tirzepatide
• You can absorb a $597 or $897 renewal charge after the introductory month
• You want a compounded-plan price that stays flat as your dose goes up
• You'd rather skip a video appointment; Pallas says 43 states allow a fully asynchronous visit

Pallas is probably not your fit if:

• You want Wegovy, Ozempic, Zepbound, or Mounjaro and qualify for a lower manufacturer program
• You need insurance billing or help with prior authorization
• You need true month-to-month billing
• You will not buy without an established independent customer-review history

Sources: Pallas Health's treatment, terms, medical-team, homepage, and clinical-disclosure pages, all read August 21, 2026. Full math and sourcing are below.

Provider-stated vs. independently checked

If compounded treatment fits you and a $597 or $897 renewal works for your budget, Pallas clears our document check. A clinician still decides whether treatment is appropriate. → Check Pallas's current pricing and eligibility (affiliate relationship)

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path, and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

Is Pallas Health legit?

Answer: Pallas Health passes a document-based legitimacy check. It publicly names its operating company, clinical network, two medical leaders with federal NPI numbers, six partner pharmacies with phone numbers, and state-by-state visit rules. That is real evidence. It does not prove that every customer has a good experience, and Pallas still lacks a deep independent customer-review history.

Let's start with the thing you actually clicked for. Is this a scam?

We found no document-based sign that Pallas is an anonymous pill seller. And we want to be precise about why, because "it has a nice website" is not evidence.

Here's what Pallas publishes about itself, and here's what we could confirm from outside sources.

The company. Pallas Health is a website. Pallas identifies the company behind it as Brentmoor, Inc., based at 131 Continental Dr, Suite 305, Newark, Delaware. Its phone number is +1 (440) 601-3717, staffed Monday through Friday, 9 to 5 Eastern. Its terms are governed by Delaware law.

The doctors. Pallas names two medical leaders: Dr. Ana Lisa Carr, MD and Dr. Kelly Tenbrink, MD. It publishes their NPI numbers — a National Provider Identifier is a ten-digit federal identifier used for U.S. healthcare providers. Pallas links Dr. Carr's NPI, 1689841744, and Dr. Tenbrink's NPI, 1346482684, directly to the federal NPPES registry.

That is useful proof that the identifiers resolve in the federal system. It is not the same as checking every state license or knowing who will treat you.

One nuance worth knowing. Pallas's medical-team page labels Dr. Carr as its Advising Physician. It does not label both named doctors that way. Pallas says every patient gets the name and license information of the specific treating clinician before a prescription is issued. Ask for it, and check that name against your own state's medical board — not just the NPI registry. An NPI is an identity record. It does not by itself prove that the person holds a current license in your state.

The certification. Pallas displays a LegitScript badge and says it is a certified healthcare merchant. A badge on a website is still just an image until you check it. Search "pallashealth.co" in LegitScript's public certification lookup before you treat the badge as proof.

Credit where it's earned. Pallas publicly names its operator, clinical network, two medical leaders, six pharmacies with phone numbers, state visit rules, and the FDA disclosure that compounded drugs are not FDA-approved. That is a strong disclosure set for a new platform. Say what you want about the pricing — and we're about to — but the disclosure deserves credit.

So: named company, named clinical network, named doctors, named pharmacies, and published terms.

The price is where the hard questions start.

Who actually prescribes it, and which pharmacy fills it?

Answer: Pallas says it does not employ medical providers and identifies the pharmacies as independent partners. Clinical care comes through Lion MD on the CareValidate platform. If a clinician prescribes treatment, one of six named partner pharmacies dispenses it. Other telehealth brands also publish Lion MD, the same two medical leaders, or overlapping pharmacies. That means some brands share infrastructure — not that every patient receives the same clinician, formulation, or medication lot.

This is the part almost nobody explains, so here it is in plain order.

The chain, top to bottom:

1. You fill out an intake form.
2. Pallas Health / Brentmoor, Inc. runs the website, your account, and your billing. It is not a medical practice.
3. A Lion MD clinician reviews your intake and decides whether to prescribe. The clinician can say no.
4. One of six partner pharmacies dispenses and ships the medication if prescribed.
5. Follow-up includes messaging, check-ins, dose-adjustment visits, and a clinician review before renewal.

The six pharmacies Pallas names:

Pallas does not promise that you can choose the pharmacy. It says the assignment depends on your medication, your shipping state, and current capacity.

The shared care stack most reviews miss

Here's where it gets interesting.

We checked other brands that publicly name Lion MD, CareValidate, Dr. Carr, Dr. Tenbrink, or overlapping pharmacy partners. We could verify four current examples besides Pallas.

Each row comes from the brand's own public page, read August 21, 2026. We removed brands from the draft when we could not reproduce the stated combination from a current first-party page.

What this means for you, in plain words: some companies you compare may share the same clinical network, physicians, platform, or pharmacy partners. You are not always comparing fully separate care systems.

But don't take that one step too far. A shared backend does not prove two brands are the same business. It does not prove your clinician will be the same. It does not prove your formula, concentration, dispensing pharmacy, support team, or medication lot will be the same.

It changes what "shopping around" means. The questions that matter become price, billing schedule, support, pharmacy assignment, exact formulation, and what happens when something goes wrong.

Five questions to ask before you pay — copy and paste these into the contact form:

1. Which pharmacy is expected to fill my prescription in my state?
2. At what point will I learn the exact pharmacy name?
3. What active ingredient, formulation, and concentration would be prescribed?
4. Will the label show my dose in both milligrams and units on the syringe?
5. Who do I contact if the package arrives warm, late, damaged, or different from the prescription?

Not sure which brands are actually different from each other? Find My GLP-1 Path compares providers by treatment type, billing, insurance help, and the care and pharmacy information they publish — not just by logo. → Get your personalized match in about 60 seconds

What do Pallas Health GLP1 reviews actually say?

Answer: Pallas does not yet have an established independent customer-review record. In searches run August 21, 2026, we found no dedicated Pallas Health profile on Trustpilot or the Better Business Bureau and no clear organic Reddit customer thread. We did find several editorial or affiliate review pages. Pallas's iPhone app now shows a 5.0 score from only two ratings. Pallas itself claims 4.8 out of 5 from more than 2,400 member reviews, but it does not publish the review platform or method behind that number.

This is the actual question you typed. So let's not bury it.

Here's what we searched, and what we found:

That's the review record we could reproduce.

What Pallas publishes about itself

Pallas's site carries five short testimonials, each with a first name and last initial, each labeled "Verified member." Here's one, so you know what they look like:

"The whole process was easier than I expected." — Sarah M., published by Pallas Health

The other four are similar: shipping was fast, the care team replies, and the process felt easy.

How to read those honestly. Pallas itself says these describe service experiences, not treatment outcomes. That's an accurate and responsible label, and we're repeating it. They are not evidence that the medication works. We did not independently confirm that these customers exist or that the quotes are complete. A company-selected testimonial is not the same as an open review profile where unhappy customers can post too.

The 4.8 out of 5 problem

Pallas's homepage says "4.8/5.0 from 2,400+ member reviews."

We could not reproduce, audit, or locate the dataset behind that score.

Here's what's missing before anyone should treat it as strong evidence:

• Which platform hosts the reviews
• How many total members were eligible to review
• What dates the reviews cover
• Whether everyone was asked, or only selected customers
• Whether negative reviews could be posted
• Who moderates them
• Whether the score covers GLP-1 care or all Pallas programs
• Whether Pallas or an outside party calculated it

We are not saying the number is false. We're saying we can't check the underlying reviews. That's a meaningful difference from a public review page where you can read the one-star reviews yourself.

The 200,000 patients problem

Pallas's homepage also says "200,000+ patients."

Now put that next to something else on Pallas's own website.

Its clinical-disclosures page, last updated June 4, 2026, says the patient portal goes live alongside "our July 2026 launch" and that existing waitlist patients will receive login credentials. Its Terms of Service were last updated July 11, 2026. Its refund policy says one deduction applies to purchases made on or after July 14, 2026.

Those documents do not prove Pallas first treated a patient in July. They do show that Pallas describes July 2026 as its launch while also advertising 200,000+ patients without defining the group or period being counted.

Both statements are on the same website. The missing piece is the definition.

We're not calling anyone a liar. The number may count a wider Brentmoor or Lion MD network, previous programs, app users, leads, or something else. But Pallas doesn't say what it counts, and a number that big with no definition is worth one email.

Here's your homework, and it's the single most useful thing on this page: email [email protected] and ask two questions.

"What does the 200,000+ patients figure count, and over what period? Which platform or dataset contains the 2,400+ member reviews behind the 4.8/5 rating?"

Save the reply. If you get a clear answer, that's a real trust signal. If you get a vague one, that's information too.

One more thing in the footer

Scroll to the bottom of any Pallas page and you'll find two disclosures most people never see.

The first says individuals shown in marketing may be actors or models. The second says some site content is AI-generated and carries no warranty about its accuracy, completeness, or reliability.

Neither disclosure is unusual on its own. Lots of companies use stock photography and software-assisted content. But the same site also shows two before-and-after stories labeled "Verified Customer." The sitewide footer does not tell the reader which images, if any, use actors or models. On a page built around testimonials, that is an avoidable evidence gap.

For context on the legal floor: the FTC's Consumer Review Rule took effect October 21, 2024. It prohibits specified fake or false reviews and testimonials and other deceptive review practices. Knowing violations can expose a business to civil penalties of up to $53,088 per violation under the current penalty amount.

We are citing the rule so you know what the legal floor is. We are not saying Pallas violated it. We have no evidence of that, and it isn't our call to make.

No call to action here on purpose. We just showed you an evidence gap. Pushing you toward a signup button in the same breath would be gross.

How much does Pallas Health really cost?

Answer: Compounded semaglutide through Pallas Health costs $139 for the first month, then $597 charged every 12 weeks. Compounded tirzepatide costs $179 first, then $897 every 12 weeks. Pallas describes the renewals as $199 and $299 per month on average. That calculation divides each 12-week renewal charge by three, even though 12 weeks is 84 days rather than three average calendar months. On a 365-day calendar basis, the renewal run rates are about $216.18 and $324.81 per month.

The ad says $139. Your card will say something else.

What actually hits your card

Prices come from Pallas's GLP-1 treatment page, read August 21, 2026. Calendar math: renewal charge ÷ 84 days × 365 days ÷ 12 months. Annualized renewal run rate: renewal charge ÷ 84 days × 365 days. These run-rate figures exclude the introductory month and are not a promise of the exact cash that will fall inside any one 12-month statement period.

The second charge is the one that surprises people

Read that table again and find the row that matters.

$139, then $597.

The second semaglutide charge is more than four times the first. For tirzepatide it's $179, then $897 — about five times the first charge.

Pallas discloses this in its pricing text and FAQ. But the large page number is the introductory price, while the renewal amount appears in smaller copy. A reader who sees "$139 first month, then $199/mo average" may picture a $199 charge next month. That is not the billing schedule Pallas publishes.

The terms say that in video-visit states, the recurring subscription begins on the clinical approval date. Confirm the exact first renewal date at checkout before you pay.

Why $199 a month isn't a calendar-month average

Here's the small math that trips everyone up.

Twelve weeks is 84 days. Three average calendar months in a 365-day year total about 91.25 days. So a 12-week cycle is more than a week shorter than a calendar quarter. You get billed more often than four times per calendar year at the standing cadence.

Run it out: $597 ÷ 84 days × 365 days = $2,594.11 a year, or $216.18 per calendar month at the renewal rate. Not $199.

For tirzepatide: $897 ÷ 84 days × 365 days = $3,897.68 a year, or $324.81 per calendar month at the renewal rate. Not $299.

The gap is about $17 to $26 a month. Small compared with the total. Still real. If you're budgeting to the dollar, use the right dollar.

The other charges to know about

• The $60 video-visit deposit. In jurisdictions that require a live video appointment, checkout may collect a $60 deposit instead of the full first payment. It is credited toward your first order if approved and refunded in full if you are declined or cancel before a clinical decision. If you miss or abandon the required visit, Pallas's terms say the deposit may be kept.
• The $5 refund fee. A qualifying cancellation refund may be reduced by third-party payment-processing costs plus $5. This does not apply when a clinician declines you or an order is unfulfilled.
• Pay-over-time. Pallas says financing is available at checkout. Read the lender's full terms, interest, fees, and payment schedule before choosing it.

What the price actually includes

To be fair to Pallas, this is a genuinely all-in listed price. The compounded-plan price covers clinician review, ongoing check-ins, dose adjustments, care-team messaging, medication when prescribed, the app, and free shipping. There is no separate membership fee stacked on top.

And the price doesn't climb as your dose climbs. Some programs charge you more at a higher dose. Pallas says its compounded-plan price stays flat across the listed doses as of August 21, 2026.

What the public plan page does not list as included is routine lab work. Ask whether labs are required for you, where they would be done, and who pays before you treat the plan as your full medical cost.

If a $597 or $897 charge every 12 weeks doesn't fit how you budget, that's a real reason to look elsewhere — not a reason to give up. Some programs bill in smaller monthly charges. → See options matched to your state and budget

Is Pallas Health expensive for Wegovy, Ozempic, Zepbound, or Mounjaro?

Answer: Yes, compared with current manufacturer programs. Pallas lists FDA-approved brand-name GLP-1 medications for $1,069 to $1,349 a month. NovoCare and LillyDirect list lower cash or savings-program prices for eligible patients. The biggest clean comparison is Wegovy: Pallas lists $1,349 a month, while NovoCare lists $199 for two eligible starter fills and then $349 for standard Wegovy pen doses — a $1,000 ongoing monthly gap.

This is the section we'd want someone to show us.

Pallas doesn't only list compounded medication. It also lists brand-name Wegovy, Ozempic, Zepbound, and Mounjaro for cash.

Here's what it charges, next to current manufacturer programs.

Pallas prices were read August 21, 2026. NovoCare and Lilly programs have eligibility rules, dose rules, refill timing, expiration dates, and the right to change or end an offer. The Mounjaro $499 figure is not a universal cash price and should not be treated as one.

Read the Wegovy row again.

One thousand dollars a month at the ongoing standard-pen price. Same FDA-approved Wegovy pen. Same listed standard dose. Different route to the box.

A new eligible NovoCare patient who receives two $199 Wegovy starter fills and then ten $349 standard pen fills would spend $3,888 for 12 medication fills. Twelve monthly fills at Pallas's published $1,349 price would total $16,188. That conditional 12-fill gap is $12,300, before adding any outside clinician or membership fee to the manufacturer route.

To be clear about what's happening: these are FDA-approved brand-name medications. Pallas isn't listing a fake version. It is listing cash prices much closer to retail while the manufacturers now run lower direct or savings routes for eligible patients.

There's nothing automatically unlawful about charging a higher cash price. But you don't have to pay it.

One medical distinction matters here: Wegovy and Zepbound are FDA-approved for chronic weight management in eligible patients. Ozempic and Mounjaro are FDA-approved for type 2 diabetes, not weight loss. A clinician may sometimes prescribe a drug off-label, but the manufacturer savings terms and insurance rules may require an FDA-approved use.

So what should you do instead?

Three options, cheapest route first when it fits.

1. Go straight to the manufacturer route. NovoCare Pharmacy and LillyDirect can fill eligible prescriptions at the published program prices. You still need a valid prescription. This is usually the cleanest cash path if you already have a clinician who will prescribe and you meet the program terms.

2. Check your insurance first. If you have commercial insurance, a covered plan plus a manufacturer savings card may beat every cash price on this page. Coverage is not guaranteed, and the medication's approved use matters.

3. Use a telehealth program that can check coverage, handle prior authorization, and pass through manufacturer cash pricing. That's where Ro can fit.

Where Ro fits

Ro's current pricing page lists its membership at $39 for the first month and says that amount is refunded if you are not eligible for GLP-1 treatment. After the first month, membership is $149 on a monthly plan or as low as an effective $74 a month with an annual plan paid upfront. Medication is billed separately.

Ro also offers a free insurance coverage check for Ozempic, Wegovy, and Zepbound pens. Its insurance page says its team handles prior-authorization paperwork when required. Coverage and prescriptions are never guaranteed.

Here's the same Wegovy pen at the ongoing $349 NovoCare price:

That is an ongoing difference of about $851 to $926 every month. The annual-prepay figure is an effective monthly amount; the membership is paid upfront.

Now the honest part, because you deserve it before you click anything.

Ro does NOT give you one simple all-in price the way Pallas does. Ro charges a membership fee plus the medication. The annual membership requires money upfront. If a single compounded-plan price, no insurance paperwork, and no separate membership matter most to you, Pallas's structure is genuinely simpler.

But for brand-name Wegovy, Ro says its cash prices use the manufacturer program, and it can also check insurance. On the published numbers above, the two-charge structure is still far cheaper than Pallas's one brand-name price. Simple isn't always cheap.

### For brand-name Wegovy or Zepbound, check the cheaper routes first. Start with the manufacturer program or your insurance. Use Ro when you want a telehealth clinician plus coverage and prior-authorization support. Read our full Ro GLP-1 review and how Ro's membership fee works before paying. → Check your GLP-1 insurance coverage with Ro (affiliate relationship; the coverage check is free)

Is compounded semaglutide still legal in 2026?

Answer: Patient-specific compounding can still be lawful, but the broad shortage-era copy market is over. Compounded semaglutide and tirzepatide are not FDA-approved. A 503A pharmacy generally compounds for an identified patient under a prescription and cannot regularly make an essentially identical copy of a commercially available approved drug. A prescriber can document a change that makes a significant difference for that patient. 503B outsourcing facilities face separate bulk-substance, shortage, and copy rules.

If you're leaning toward the compounded plan, you need to understand what you're actually buying. Here it is without the legal fog.

First, definitions. A compounded medication is prepared by a pharmacy or outsourcing facility for a clinical need. A 503A pharmacy generally compounds for an identified patient under a prescription and is mainly overseen by state boards, with federal law still applying. A 503B outsourcing facility may make larger batches, must register with the FDA, and is subject to current good manufacturing practice requirements.

Compounded drugs are not FDA-approved. The FDA does not review each compounded drug for safety, effectiveness, or quality before it is marketed.

What changed. During the shortages, the FDA gave compounders limited enforcement discretion tied to the shortage list. Those windows ended:

• Tirzepatide: February 18, 2025 for 503A compounders and March 19, 2025 for 503B outsourcing facilities
• Semaglutide injection: April 22, 2025 for 503A compounders and May 22, 2025 for 503B outsourcing facilities

What's allowed now. Federal law limits regular compounding of drugs that are essentially copies of commercially available approved products. Under the patient-specific 503A exception, a prescriber may document that a change produces a significant difference for that individual patient. FDA examples include changing an ingredient because of an allergy. Cost alone is not the patient-specific clinical difference described in the law and guidance.

Pallas says this itself. Its terms and clinical disclosures state that a treating clinician must document a patient-specific clinical need and that pricing alone is not a basis for compounding. Pallas also says compounded products are not FDA-approved, are not generic versions of Ozempic, Wegovy, Mounjaro, or Zepbound, and have not been reviewed by the FDA for safety, effectiveness, or quality.

That wording keeps the compounded product separate from FDA-approved brands. We'll give Pallas credit for saying it plainly.

So ask the question the law implies. When a Pallas clinician approves a compounded product, ask:

"What patient-specific clinical need is documented for this compounded product instead of an FDA-approved option?"

Then ask for the exact active ingredient and formulation. The FDA says semaglutide sodium and semaglutide acetate are different active ingredients from the semaglutide base used in approved drugs and that it is not aware of a lawful basis for using those salt forms in compounding.

What's coming next

This matters if you're about to commit to a plan.

On April 30, 2026, the FDA proposed not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List. That list controls which bulk drug substances outsourcing facilities may use when the separate shortage exception does not apply. The FDA later extended the public comment deadline to July 30, 2026.

As of our August 21, 2026 verification, we found the proposal and the closed comment period, but no final Federal Register determination. So it is still a proposal, not a final rule.

If finalized as proposed, it would keep those active ingredients off the 503B Bulks List. That would further limit when a 503B outsourcing facility could compound from bulk active ingredient outside a shortage. It would not erase every lawful form of patient-specific compounding or every pathway that starts with an FDA-approved product.

What the FDA's current safety data does — and does not — show

As of May 31, 2026, the FDA says it had received:

• 990 adverse-event reports associated with compounded semaglutide
• More than 730 adverse-event reports associated with compounded tirzepatide

Those are reports, not proof that the compounded product caused every event. The FDA says it is not always possible to tell whether the drug caused the event or whether other factors contributed. Reporting is also incomplete because many state-licensed pharmacies are not required to send adverse-event reports to the FDA.

The agency has separately warned about dosing errors, including hospitalizations, when patients or clinicians confuse milligrams, units, concentrations, or multidose-vial measurements. That is why the label and dosing questions earlier on this page matter.

We are not telling you every compounded medication is dangerous. We are telling you that it does not receive FDA premarket approval, the legal category is narrower than it was during the shortage, and the exact pharmacy, active ingredient, concentration, label, and patient-specific reason deserve real answers before you prepay.

Can you cancel Pallas Health and get a refund?

Answer: Yes, Pallas says you can cancel at any time, and cancelling itself is free. Cancellation takes effect at the end of the current billing period. If a clinician declines to prescribe or an order is not fulfilled and shipped, you are refunded in full. But once medication has been dispensed and shipped, Pallas's terms say it cannot be returned or refunded except where law requires it.

Cancellation is where "cancel anytime" and reality can drift apart. Here's the actual map, straight from Pallas's Terms of Service, last updated July 11, 2026.

The $5 deduction applies to purchases made on or after July 14, 2026. It does not apply to clinician-declined or unfulfilled orders.

What "cancel anytime — no hidden fees" doesn't mean. Pallas uses that phrase on its homepage. It does not mean:

• Your paid period ends immediately
• You automatically get a prorated refund
• You get money back after medication has been dispensed and shipped
• Every qualifying cancellation refund returns at 100 cents on the dollar

That last one is the gap. A $5 fee plus payment-processing costs isn't a scandal. It's just not the same thing as a full refund.

Now here's something Pallas does well

We spend a lot of this page pointing out problems, so let's be even-handed.

The Pallas Terms of Service we reviewed on August 21, 2026 contain no forced-arbitration clause and no class-action waiver.

Those clauses can limit where and how a dispute is heard. Pallas's current terms do not ask you to waive those routes. Its liability cap is the amount you paid in the prior 12 months.

Terms can change. Treat this as a dated finding, not a forever promise.

Before you pay, screenshot four things: the price shown, the renewal date at checkout, the compounded-drug disclosure, and the date on the terms page. It takes 30 seconds and gives you a paper trail if anything goes sideways.

Read the current terms yourself before you start. We'd rather you read Pallas's own cancellation language than take ours for it. → Read Pallas Health's current Terms of Service

Who is Pallas Health right for, and who should skip it?

Answer: Pallas fits some cash-paying adults who want a compounded injection, can absorb a $597 or $897 charge every 12 weeks, and are comfortable using a young service without a deep independent review record. It is a poor fit for people who want the lowest current brand-name cash price, need insurance help, need small monthly charges, or require a long public track record before buying.

Find your row. Then do that thing.

We'd rather lose you to the right answer than keep you on the wrong one. If three of those rows describe you and none of them point to Pallas, close this tab and go do the thing that actually fits. That's the whole job of this page.

What is the RX Index Score for Pallas Health?

Answer: Pallas Health receives a provisional RX Index Score of 69 out of 100. The score rates providers on five pillars: clinical legitimacy, care quality, transparency, access, and cost. This is a document-based editorial score built from Pallas's disclosures, terms, pricing, app listings, and public records verified on August 21, 2026. It is not a customer rating or a measure of medical outcomes.

What this score is not. It isn't a customer rating. It isn't a medical outcome measure. It's our editorial read of dated, checkable facts, and we're labeling it provisional because we haven't completed a live checkout, support test, shipment, or cancellation test.

What would raise it: a public, auditable customer-review dataset; checkout language that puts the full renewal amount beside the headline price; competitive brand-name pricing; and firsthand support and cancellation results.

What would lower it: a renewal date that differs from the checkout disclosure; cancellation that is harder than the terms state; a different pharmacy or formula than the one disclosed before fulfillment; or evidence that the public review and patient-count claims cannot be supported.

How we reviewed Pallas Health

Answer: This is a document-based independent review, not a firsthand enrollment test and not a review of whether any medication works. We read Pallas Health's public pages, terms, medical-team page, homepage, and clinical disclosures on August 21, 2026. We followed its two NPI links to the federal registry, checked the six named pharmacies, compared current manufacturer prices, checked Ro's current pricing and coverage tools, reviewed the Apple and Google app listings, checked current FDA and FTC sources, and searched for independent customer-review profiles.

### What we actually verified

• Current Pallas prices and the 12-week renewal schedule
• Terms of Service, refund rules, recurring billing, and the $60 deposit clause
• Pallas's two federal NPI links
• The six named partner pharmacies and the 8 video-visit jurisdictions
• NovoCare's current Wegovy and Ozempic program prices
• LillyDirect's current Zepbound prices and Mounjaro savings eligibility
• Ro's current membership price and free coverage checker
• Four other brands publishing overlapping Lion MD, CareValidate, physician, or pharmacy details
• Current FDA shortage-enforcement dates, compounding guidance, adverse-event totals, salt-form warning, and the pending 503B proposal
• Current FTC Consumer Review Rule penalty amount
• Apple and Google Play listings for the Pallas app
• No dedicated Pallas Trustpilot or BBB profile found in searches run August 21, 2026

### What we did NOT test

• The intake experience or approval rate
• Shipping speed, temperature, or packaging
• The medication itself
• Support response time
• The cancellation interface
• How fast refunds post
• Whether Pallas's testimonials are authentic or complete
• The full review dataset behind 4.8/5 from 2,400+ reviews
• What the 200,000+ patient figure counts
• Medical outcomes of any kind

Written and verified by the editorial team at The RX Index. Commercial facts were checked against Pallas Health's own published materials on August 21, 2026. Medical and regulatory statements were checked against FDA and manufacturer sources. We claim no medical credential, this page is not medically reviewed, and it is not medical advice.

Why this page exists: Pallas's starting price is easy to find. The renewal charge, company structure, pharmacy assignment, refund limits, review evidence, compounding rules, and brand-name price gap are spread across many documents and require math. Somebody had to put them in one place.

Final verdict on Pallas Health

Answer: Pallas Health passes a document-based legitimacy check and has not yet passed a track-record check. Its operator, clinical network, named medical leaders, pharmacies, states, prices, and terms are publicly traceable. Its strongest offer is the all-in, flat-dose compounded plan. Its biggest weaknesses are an unaudited review and patient-count story, a $597 or $897 charge every 12 weeks rather than monthly billing, and brand-name prices far above current manufacturer programs.

Let's put it in one paragraph.

Pallas is not an anonymous pill site. It is a new, unusually well-documented telehealth storefront using a clinical and pharmacy network that overlaps with other brands. When compounded semaglutide or tirzepatide is the goal, you're comfortable with the 12-week charge, a clinician documents a patient-specific need, and you understand that the independent customer-review record is still thin, Pallas is a reasonable option to compare. Its current terms also contain no forced-arbitration clause or class-action waiver.

For brand-name Wegovy or Zepbound, do not start with Pallas's cash price. Start with the manufacturer program and insurance. On Wegovy alone, the ongoing published gap is about $1,000 a month before any separate clinician or membership cost.

And if you're reading this at 11 p.m. with a card sitting next to your laptop, wondering whether you're about to make a mistake — you're not overthinking it. Checking before you hand a company your health history and your card number is exactly what a smart person does. You did the right thing.

Now go do the version of this that actually fits you.

### Ready to choose the right path? For compounded care: Pallas clears our document check, but confirm the exact renewal date, pharmacy, formulation, patient-specific reason, and refund terms before paying. → Check current Pallas pricing (affiliate relationship) For brand-name medication or insurance help: check the manufacturer price and coverage first. → Check coverage with Ro (affiliate relationship; coverage check is free) A licensed clinician decides whether treatment is right for you. Approval and insurance coverage are not guaranteed. Confirm the total due, renewal date, pharmacy, medication, and refund terms at checkout before you pay.

Pallas Health FAQ

Answer: These are the questions people ask after reading a Pallas Health review — pricing details, pharmacy questions, reviews, cancellation rules, and how compounded medication differs from FDA-approved brands. Every answer below reflects information checked on August 21, 2026.

Is Pallas Health a real company? Pallas Health passes a document-based legitimacy check. It says it is operated by Brentmoor, Inc., names Lion MD and CareValidate as its clinical stack, publishes two medical leaders with federal NPI links, names six pharmacy partners, and provides contact details and terms. That does not guarantee a good customer experience.

Are there real Pallas Health GLP1 reviews anywhere? There is not yet a deep independent customer-review record. We found no dedicated Pallas profile on Trustpilot or BBB and no clear organic Reddit customer thread in searches run August 21, 2026. The iPhone app has a 5.0 score from only two ratings. Several editorial and affiliate reviews exist, and Pallas publishes its own testimonials.

Is Pallas Health legit or a scam? It passes our document check. We found a named operator, clinical group, physicians with federal identifiers, six pharmacies, a public terms page, and specific FDA disclosures. The main concerns are pricing, billing cadence, and limited independent customer history — not a missing corporate or clinical trail.

How much does Pallas Health cost per month? Compounded semaglutide is $139 for the first month, then $597 every 12 weeks. That renewal cadence equals about $216.18 per calendar month on a 365-day run-rate basis. Compounded tirzepatide is $179 first, then $897 every 12 weeks, or about $324.81 per calendar month at the renewal rate. Brand-name options are listed at $1,069 to $1,349 a month.

Why is Pallas billed every 12 weeks instead of monthly? Pallas structures its compounded renewals as 12-week supply cycles. That is why the stated "$199/month average" appears as a single $597 charge. Twelve weeks is 84 days, which is shorter than three average calendar months, so the calendar-month run rate is higher than $199.

Does the price go up as my dose increases? Pallas says no for its compounded plans. The published price stays flat across listed doses. Brand-name cash prices vary by product and may vary by dose through manufacturer programs.

Does Pallas Health take insurance? No. Pallas is cash-pay only and does not bill insurance. A separate provider or manufacturer route may be better when insurance coverage or prior authorization matters.

Can I use HSA or FSA funds? Pallas advertises HSA and FSA eligibility and says a Letter of Medical Necessity may be required. Your plan administrator decides whether a card transaction or reimbursement qualifies. Check before you count on it.

What pharmacy does Pallas Health use? One of six named partners: Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub, or Foothills Pharmacy. Pallas says the assignment depends on medication, shipping state, and capacity. Its public page does not promise that you can choose the pharmacy.

Who prescribes the medication? A clinician in the Lion MD network. Pallas itself says it is a technology platform and does not employ medical providers or make medical decisions. Ask for your specific clinician's name and license number and check the appropriate state medical board.

What states does Pallas Health serve? Pallas says all 50 states plus Washington, DC. It says 43 states allow a fully asynchronous visit.

Which states require a video visit? Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota, West Virginia, and Washington, DC. In those jurisdictions, checkout may collect a $60 deposit instead of the full first payment.

Can I cancel Pallas Health anytime? Pallas says yes. Cancellation takes effect at the end of the current billing period, not immediately. If a clinician declines or the order is unfulfilled, you get a full refund. A qualifying cancellation refund before filling may be reduced by processing costs and $5.

Can I return medication after it ships? Generally no. Pallas's terms say medication that has been dispensed and shipped cannot be returned or refunded except where law requires it.

Are Pallas's compounded medications FDA-approved? No. Compounded medications are not FDA-approved, are not generic versions of Wegovy, Ozempic, Zepbound, or Mounjaro, and are not reviewed by the FDA for safety, effectiveness, or quality before marketing. Pallas states this on its own site.

What patient-specific reason does Pallas require for compounding? Pallas says a treating clinician must document a patient-specific clinical need and that price alone is not enough. The exact reason will depend on the individual. Ask the prescriber what is documented for you.

Does Pallas use semaglutide sodium or semaglutide acetate? Pallas's public treatment page does not identify the exact active-ingredient form for every future prescription. Ask for the active ingredient and pharmacy before paying. The FDA says semaglutide sodium and acetate are different active ingredients from the semaglutide base in approved drugs and that it is not aware of a lawful basis for their use in compounding.

Does Pallas include lab work? The public compounded-plan page lists clinician review, medication when prescribed, check-ins, dose adjustments, messaging, app access, and shipping. It does not list routine lab work as included. Ask whether your clinician will require labs and who pays.

Does Pallas Health offer Wegovy or Zepbound? Yes. Pallas lists Wegovy and Zepbound as monthly cash-pay options. But its published prices are much higher than current NovoCare and LillyDirect program prices for eligible patients. A clinician decides whether a medication is appropriate.

Does Pallas offer Ozempic or Mounjaro for weight loss? Pallas lists both products on its GLP-1 treatment page. Ozempic and Mounjaro are FDA-approved for type 2 diabetes, not weight loss. Any off-label prescription is a clinician's decision, and insurance or savings programs may require an approved use.

Is Pallas Health cheaper than Ro? The comparison is not one-to-one. Pallas's compounded price is all-in. Ro's Wegovy price adds a separate membership to an FDA-approved medication. At the ongoing $349 Wegovy pen price, Ro totals about $423 with its annual prepaid membership or $498 with monthly membership, versus Pallas's listed $1,349.

How fast does Pallas ship? Pallas says medication often ships within about a week after approval. We haven't placed an order, so that is a provider-stated estimate, not a tested result.

Is Pallas Health LegitScript certified? Pallas displays a LegitScript badge and states that it is certified. Check the domain in LegitScript's public lookup before relying on the badge.

Still deciding?

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

You've read this whole thing, which means you're taking this seriously. Find My GLP-1 Path uses your state, insurance situation, budget, billing preference, and whether you want FDA-approved or compounded medication to point you toward the next step.

→ Get your personalized action plan

Sources

• Pallas Health — GLP-1 treatment and pricing, read August 21, 2026
• Pallas Health — Terms of Service, last updated July 11, 2026 and read August 21, 2026
• Pallas Health — Clinical disclosures, last updated June 4, 2026 and read August 21, 2026
• Pallas Health — Medical team, read August 21, 2026
• Pallas Health — Homepage, read August 21, 2026
• Pallas Health — Wegovy page, read August 21, 2026
• Pallas Health — Zepbound page, read August 21, 2026
• NPPES National Provider Identifier Registry
• Apple App Store — Pallas Health: Calorie Counter, read August 21, 2026
• Google Play — Pallas Health: Calorie Counter, read August 21, 2026
• NovoCare Pharmacy — Wegovy and Ozempic self-pay pricing, read August 21, 2026
• LillyDirect — Zepbound pricing, read August 21, 2026
• Mounjaro — savings and coverage terms, read August 21, 2026
• Ro — Weight Loss Program Pricing, read August 21, 2026
• Ro — GLP-1 Insurance Coverage Checker, read August 21, 2026
• FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, updated through May 31, 2026 data
• FDA — FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
• Federal Register — proposed exclusion of semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, May 1, 2026
• Federal Register — extension of the 503B proposal comment period, June 26, 2026
• FTC — Consumer Reviews and Testimonials Rule: Questions and Answers
• FTC — current $53,088 civil-penalty warning for the Consumer Review Rule
• Breeze Meds — clinical disclosures, read August 21, 2026
• SynergyRx — clinical disclosures, read August 21, 2026
• CareBareRX — FAQ and clinical disclosures, read August 21, 2026
• BridgeWell — clinical disclosures, read August 21, 2026

Prices, policies, and public records change. If you spot something out of date, send the source and we will recheck it and update the visible verification date.